ARTICLE | Company News
Cell Therapeutics submits NDA
March 29, 2000 8:00 AM UTC
CTIC submitted an NDA to the FDA for its ArsenicTrioxide (ATO) to treat patients with relapsed or refractory acute promyelocytic leukemia. The product has fast track designation. ...